ASCO 2021: Updated Results of CheckMate 9LA Show Maintained Benefit With Nivolumab-Ipilimumab Plus Chemotherapy in Non-Small Cell Lung Cancer
Treatment discontinuation due to adverse events had no impact on efficacy outcomes
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.